Alpha Tau Medical Ltd. (DRTS)
$3.78
-0.20 (-5.03%)
Rating:
Recommendation:
-
| Symbol | DRTS |
|---|---|
| Price | $3.78 |
| Beta | 0.000 |
| Volume Avg. | 0.08M |
| Market Cap | 260.864M |
| Shares () | - |
| 52 Week Range | 3.0-20.65 |
| 1y Target Est | - |
| DCF Unlevered | DRTS DCF -> | |
|---|---|---|
| DCF Levered | DRTS LDCF -> | |
| ROE | - | |
| ROA | - | |
| Operating Margin | - | |
| Debt / Equity | 11.29% | Neutral |
| P/E | - | |
| P/B | - |
Latest DRTS news
About
Download (Excel)Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.